Drug intelligence / Profile preview

cenvacibart

Development stage: Phase 3
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Cenvacibart (REGN7508) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals that targets coagulation factor XI (FXI). By inhibiting FXI, cenvacibart aims to prevent the formation of blood clots (thrombosis) while potentially minimizing the risk of bleeding compared to traditional anticoagulants. It is currently being evaluated in Phase 3 clinical trials (such as ROXI-APEX) for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery, such as total knee arthroplasty.

Other names: cenvacibart

Targets

Factor XIaF11 (Coagulation Factor XI)

Beyond the preview

Go deeper on cenvacibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cenvacibart.

Explore the full profile